相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Rapid and profound potentiation of Apo2L/TRAIL-mediated cytotoxicity and apoptosis in thoracic cancer cells by the histone deacetylase inhibitor Trichostatin A: the essential role of the mitochondria-mediated caspase activation cascade
Rishindra M. Reddy et al.
APOPTOSIS (2007)
Enhancement of Apo2L/TRAIL-mediated cytotoxicity in esophageal cancer cells by cisplatin
Wilson S. Tsai et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Valproic acid, an antiepileptic drug with histone deacetylase inhibitory activity, potentiates the cytotoxic effect of Apo2L/TRAIL on cultured thoracic cancer cells through mitochondria-dependent caspase activation
M. Firdos Ziauddin et al.
NEOPLASIA (2006)
Tumor-specific apoptotic gene targeting overcomes radiation resistance in esophageal adenocarcinoma
JY Chang et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2006)
Cisplatin-dependent upregulation of death receptors 4 and 5 augments induction of apoptosis by TNF-related apoptosis-inducing ligand against esophageal squamous cell carcinoma
K Kondo et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
Radiotherapy sensitization by tumor-specific TRAIL gene targeting improves survival of mice bearing human non-small cell lung cancer
XC Zhang et al.
CLINICAL CANCER RESEARCH (2005)
Reactive oxygen species regulate caspase activation in tumor necrosis factor-related apoptosis-inducing ligand-resistant human colon carcinoma cell lines
K Izeradjene et al.
CANCER RESEARCH (2005)
HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo
L Pukac et al.
BRITISH JOURNAL OF CANCER (2005)
Resveratrol-mediated sensitisation to TRAIL-induced apoptosis depends on death receptor and mitochondrial signalling
S Fulda et al.
EUROPEAN JOURNAL OF CANCER (2005)
Bcl-2 overexpression enhances tumor-specific T-cell survival
J Charo et al.
CANCER RESEARCH (2005)
Suppression of pancreatic tumor growth in the liver by systemic administration of the TRAIL gene driven by the hTERT promoter
D Jacob et al.
CANCER GENE THERAPY (2005)
Toxic proteins released from mitochondria in cell death
X Saelens et al.
ONCOGENE (2004)
Enhancement of therapeutic potential of TRAIL by cancer chemotherapy and irradiation: mechanisms and clinical implications
S Shankar et al.
DRUG RESISTANCE UPDATES (2004)
Cotreatment with histone deacetylase inhibitor LAQ824 enhances apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells
F Guo et al.
CANCER RESEARCH (2004)
Anti-liver cancer activity of TNF-related apoptosis-inducing ligand gene and its bystander effects
Chao He et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2004)
Targeting death receptors in cancer with Apo2/TRAIL
SK Kelley et al.
CURRENT OPINION IN PHARMACOLOGY (2004)
Drug-mediated sensitization to TRAIL-induced apoptosis in caspase-8-complemented neuroblastoma cells proceeds via activation of intrinsic and extrinsic pathways and caspase-dependent cleavage of XIAP, Bcl-xL and RIP
A Mühlethaler-Mottet et al.
ONCOGENE (2004)
Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand cooperates with chemotherapy to inhibit orthotopic lung tumor growth and improve survival
H Jin et al.
CANCER RESEARCH (2004)
Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies
S Inoue et al.
CELL DEATH AND DIFFERENTIATION (2004)
Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs
TM Ganten et al.
CELL DEATH AND DIFFERENTIATION (2004)
The proteasorne inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP
TJ Sayers et al.
BLOOD (2003)
Mechanisms of cytochrome c release by proapoptotic BCL-2 family members
L Scorrano et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2003)
Chemotherapy enhances TNF-related apoptosis-inducing ligand DISC assembly in HT29 human colon cancer cells
S Lacour et al.
ONCOGENE (2003)
A unified model for apical caspase activation
KM Boatright et al.
MOLECULAR CELL (2003)
A mechanism of resistance to TRAIL/Apo2L-induced apoptosis of newly established glioma cell line and sensitisation to TRAIL by genotoxic agents
Y Arizono et al.
BRITISH JOURNAL OF CANCER (2003)
Apo2L/TRAIL and its death and decoy receptors
HN LeBlanc et al.
CELL DEATH AND DIFFERENTIATION (2003)
Intravascular adenoviral agents in cancer patients: Lessons from clinical trials
T Reid et al.
CANCER GENE THERAPY (2002)
Long-term tumor-free survival from treatment with the GFP-TRAIL fusion gene expressed from the hTERT promoter in breast cancer cells
TY Lin et al.
ONCOGENE (2002)
Defining characteristics of Types I and II apoptotic cells in response to TRAIL
N Özören et al.
NEOPLASIA (2002)
The role of mitochondrial factors in apoptosis: a Russian roulette with more than one bullet
G van Loo et al.
CELL DEATH AND DIFFERENTIATION (2002)
Chemotherapeutic agents sensitize osteogenic sarcoma cells, but not normal human bone cells, to Apo2L/TRIAL-induced apoptosis
A Evdokiou et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression
S Fulda et al.
ONCOGENE (2002)
Resistance of prostate cancer cells to soluble TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) can be overcome by doxorubicin or adenoviral delivery of full-length TRAIL
C Voelkel-Johnson et al.
CANCER GENE THERAPY (2002)
Tumor-cell resistance to death receptor-induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax
H LeBlanc et al.
NATURE MEDICINE (2002)
Clinical evaluation of adenoviral-mediated p53 gene transfer: Review of INGN 201 studies
JA Merritt et al.
SEMINARS IN ONCOLOGY (2001)
Tumor necrosis factor-related apoptosis-inducing ligand and chemotherapy cooperate to induce apoptosis in mesothelioma cell lines
WH Liu et al.
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY (2001)
Pro-apoptotic cascade activates BID, which oligomerizes BAK or BAX into pores that result in the release of cytochrome c
SJ Korsmeyer et al.
CELL DEATH AND DIFFERENTIATION (2000)
BID-dependent and BID-independent pathways for BAX insertion into mitochondria
SC Ruffolo et al.
CELL DEATH AND DIFFERENTIATION (2000)
分享论文
